|
|
A2A adenosine receptor protects tumors
from antitumor T cells
Akio Ohta1,2,
Elieser Gorelik3, Simon J. Prasad4,
Franca Ronchese4, Dmitriy Lukashev1,2,
Michael K. K. Wong3,5, Xiaojun Huang3,
Sheila Caldwell6, Kebin Liu6,7,
Patrick Smith1, Jiang-Fan Chen8,
Edwin K. Jackson9, Sergey Apasov1,
Scott Abrams6, and Michail Sitkovsky1,2,*
1Laboratory of
Immunology, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD 20892; 2New
England Inflammation and Tissue Protection Institute, Northeastern
University, Boston, MA 02115; 3Department of Pathology and
University of Pittsburgh Cancer Institute, University of Pittsburgh,
Pittsburgh, PA 15213; 4Malaghan Institute of Medical
Research, Wellington, New Zealand; 5Department of Medicine
and Department of Pharmacology and Therapeutics, Roswell Park Cancer
Institute, Buffalo, NY 14263; 6Laboratory of Tumor
Immunology and Biology, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, MD 20892; 7Department
of Biochemistry and Molecular Biology, Medical College of Georgia,
Augusta, GA 30912; 8Department of Neurology, Boston
University School of Medicine, Boston, MA 02118; and 9Center
for Clinical Pharmacology, Departments of Pharmacology and Medicine,
University of Pittsburgh Cancer Institute, University of Pittsburgh,
Pittsburgh, PA 15213 -- *To whom correspondence should be addressed
at: New England Inflammation and Tissue Protection Institute,
Northeastern University, 360 Huntington Avenue, 113 Mugar Life
Sciences Building, Boston, MA 02115. Michail Sitkovsky, E-mail: m.sitkovsky@neu.edu
-- Communicated by William E. Paul, National Institutes of
Health, Bethesda, MD, June 22, 2006 (received for review
March 29, 2006).
|
